148 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
CRSP CRISPR Therapeutics AG $50.31 $2.39B N/A
Article Searches
Here's Why Vertex Pharmaceuticals Rose 13.4% in November https://www.fool.com/investing/2019/12/04/heres-why-vertex-pharmaceuticals-rose-134-in-novem.aspx?source=iedfolrf0000001 Dec 04, 2019 - The rare-disease specialist is putting together a respectable end-of-year run.
Biotech Tops in November: Best ETFs & Stocks http://www.zacks.com/stock/news/646838/biotech-tops-in-november-best-etfs-stocks?cid=CS-ZC-FT-etf_news_and_commentary-646838 Nov 29, 2019 - The biotech space of the broad healthcare sector outperformed others in November, courtesy of a series of positive news including study results, regulatory backdrop and deal activities.
The Zacks Analyst Blog Highlights: GLD, CRSP, GBT, ALNY and ARKG http://www.zacks.com/stock/news/646789/the-zacks-analyst-blog-highlights-gld-crsp-gbt-alny-and-arkg?cid=CS-ZC-FT-press_releases-646789 Nov 29, 2019 - The Zacks Analyst Blog Highlights: GLD, CRSP, GBT, ALNY and ARKG
Why Gold is Headed to Zero -- And What You Should Buy Instead http://www.zacks.com/commentary/643895/why-gold-is-headed-to-zero-and-what-you-should-buy-instead?cid=CS-ZC--investment_ideas-643895 Nov 27, 2019 - Why Gold is Headed to Zero -- And What You Should Buy Instead
CRISPR vs. Gene Therapy Round 1: What Investors Need to Know https://www.fool.com/investing/2019/11/26/crispr-vs-gene-therapy-round-1-what-investors-need.aspx?source=iedfolrf0000001 Nov 26, 2019 - There’s still a long way to go, but the newcomer is off to a good start.
Genomics ETFs Surge on CRISPR's Gene Editing Progress http://www.zacks.com/stock/news/637553/genomics-etfs-surge-on-crisprs-gene-editing-progress?cid=CS-ZC-FT-etf_news_and_commentary-637553 Nov 25, 2019 - The release of encouraging data on the CRISPR/Cas9 gene-editing therapy CTX001 for two severe blood disorders puts emphasis on some genomic ETFs.
Vertex (VRTX) Gets French Reimbursement for CF Drug Orkambi http://www.zacks.com/stock/news/631140/vertex-vrtx-gets-french-reimbursement-for-cf-drug-orkambi?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-631140 Nov 21, 2019 - The French reimbursement for Vertex's (VRTX) cystic fibrosis medicine Orkambi removes a key overhang for the stock.
Vertex, CRISPR's Gene Editing Drug Shows Positive Early Data http://www.zacks.com/stock/news/629127/vertex-crisprs-gene-editing-drug-shows-positive-early-data?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-629127 Nov 20, 2019 - Vertex (VRTX) and partner CRISPR Therapeutics announce positive early data from two studies on gene-editing drug CTX001 for the treatment of beta-thalassemia and sickle cell disease.
Company News For Nov 20, 2019 http://www.zacks.com/stock/news/629344/company-news-for-nov-20-2019?cid=CS-ZC--corporate_summary-629344 Nov 20, 2019 - Companies in the news are: AMD, SAEX, DSS, CRSP
Biotech Stock Roundup: MYOV & KRTX Surge, Pipeline Updates From VRTX, CELG & More http://www.zacks.com/stock/news/629204/biotech-stock-roundup-myov-krtx-surge-pipeline-updates-from-vrtx-celg-more?cid=CS-ZC-FT-analyst_blog|stock_roundup-629204 Nov 20, 2019 - Key highlights of the past week include regulatory and pipeline updates along with collaboration deals.

Pages: 123456...15

Page 1>